Navigation Links
Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
Date:9/6/2013

SAN DIEGO, Sept. 6, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced the 2nd Annual Sickle Cell Disease Therapeutics Conference will take place on September 19th, 2013 at the Four Seasons Hotel in New York City (Cosmopolitan Suite). The conference is intended to serve as a forum to raise awareness for sickle cell disease and will include presentations from leading companies in sickle cell disease and discussions with experts regarding the latest advancements and trends in treatment.  Conference sponsors include The Pierre Fabre Foundation, Canaccord Genuity, Piper Jaffray, Sheppard Mullin Richter & Hampton, LLP, Pharm-Olam International and Theradex Systems, Inc.

Six public and private companies developing new treatment options for patients with sickle cell disease, including bluebird bio (NASDAQ GS: BLUE) and Mast Therapeutics, Inc. (NYSE MKT: MSTX) will be presenting. 

Conference attendees will hear from leaders in the sickle cell disease medical and advocacy communities, including:

  • Althea Grant, PhD, Chief of the Epidemiology and Surveillance Branch in the Division of Blood Disorders of the National Center on Birth Defects and Developmental Disabilities at the Centers for Disease Control
  • Wally R. Smith, MD, Professor of Medicine at Virginia Commonwealth University
  • Susan P. Perrine, MD, Professor, Pediatrics, Medicine, Pharmacology and Experimental Therapeutics Cancer Center; Director, Hemolgobinopathy Thalassemia Research Unit at the Boston University School of Medicine
  • Gary A. Gibson, President & CEO of The Martin Center Sickle Cell Initiative
  • Beatrice Garrette, Directrice Generale, The Pierre Fabre Foundation
  • Nirmish Shah, MD, Assistant Professor, Director of Sickle Cell Transition, Program, Division of Hematology, Division of Pediatric Hematology/Oncology at Duke University

Question & answer sessions will be moderated by the following healthcare analysts:

  • Ritu S. Baral, Managing Director, Senior Analyst, Biotechnology Equity Research, Canaccord Genuity
  • Edward A. Tenthoff, Managing Director and Senior Research Analyst, Piper Jaffray

"The Mast team is deeply committed to advancing the research and care of patients with sickle cell disease. Our commitment includes conducting one of the largest pivotal clinical studies in sickle cell disease crisis intervention (EPIC) with our lead product candidate MST-188, creating and hosting the Annual Sickle Cell Disease Therapeutics Conference and sponsoring and supporting sickle cell community based organizations and events across the country," stated Brian M. Culley, Chief Executive Officer of Mast Therapeutics. "This disease was identified over one hundred years ago, but only one FDA-approved drug is available, and none are available to treat an on-going vaso-occlusive crisis or the underlying ischemia and infarction that play a role in reducing the average life expectancy to around 45 years.  Awareness leads to investment, development, and eventually, to new treatments. This conference offers an excellent forum for investors and potential partners to review the latest advancements for patients suffering with this rare disease."

More information can be found on the conference web site at www.scdconference.com.  

About Mast Therapeutics

Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow).  

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in early 2014.  More information can be found on the Company's web site at www.masttherapeutics.com.

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements

Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the Company's development plans for MST-188 in acute limb ischemia, including the timing of initiation of the planned phase 2 study.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: delays in the commencement of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects and manufacturing sufficient quantities of clinical trial material; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of a planned clinical study; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law. 

(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)


'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... Young Asset Protection, an insurance provider and ... greater Pittsburgh metropolitan region, is joining forces with the local chapter of the ... , Variety the Children’s Charity is a national organization dedicated to empowering, enabling, ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Hong Kong Polytechnic University (PolyU) ... facility among higher education institutions in Hong Kong to support teaching, learning and research. ... range and quantity of facilities in Hong Kong. , With an area of ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... Joseph Health held the much anticipated Regional Primary Care Spring Symposium on April ... in the local medical community, offering physicians and healthcare providers an opportunity to ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... to experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become ... privilege to help my numerous clients over the years with all their dental needs,” ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Detroit reveals good news for older shoulder replacement patients; post-operative recovery just might ... from two groups of patients presenting with osteoarthritis following surgery: 262 patients under ...
Breaking Medicine News(10 mins):